Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
Takayuki KatsubeYuji InoueTakahiro FukuharaTakeshi KanoToshihiro WajimaPublished in: European journal of clinical pharmacology (2020)
In consideration with in vitro data, the in vivo and in silico results suggested no clinically significant DDI potential of lusutrombopag with other medical products via metabolic enzymes and transporters.